Vendor, San Mateo, CA
Revagenix Inc.
UEI D98QFZUPFXJ9, CAGE 8B1Y9
2 awards and $32,815,535 obligated between February 16, 2024 and July 10, 2026, 100% under full and open competition, against 21.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $32,815,535 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Hear when Revagenix Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Revagenix Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 2
- Obligated so far
- $32,815,535
- Soonest
- October 31, 2026
The 2 contracts, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) to National Institutes of Health, by dollars.
| Leidos Biomedical Research Inc.Frederick, MD | $2,186,369,442 |
| Westat, Inc.Rockville, MD | $760,724,225 |
| Technical Resources International, Inc.Bethesda, MD | $196,391,189 |
| Duke UniversityDurham, NC | $158,758,507 |
| MriglobalKansas City, MO | $117,921,746 |
| The Johns Hopkins UniversityBaltimore, MD | $100,932,043 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93022C00061Definitive Contract, February 16, 2024, Full and Open Competition, 30 offers | National Institutes of Health NiaidNational Institutes of Health | A Novel LPXC Inhibitor with Pan-Resistant Pseudomonas and Burkholderia Activity.NAICS 541715, PSC AN12 | $23,368,476 |
| 75N93020C00018Definitive Contract, February 23, 2024, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | To Select a Novel Small Molecule Antibiotic for Clinical Development and Advance IT Through Ind Filing and Phase 1 Clinical Studies.NAICS 541715, PSC AN12 | $9,447,059 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 22 across 2 awards